Randomized Study of Rituximab-ICE versus Gemcitabine, Methylprednisolone, and Cisplatin in Patients with Recurrent / Refractory CD20+ Diffuse Large B-Cell Lymphoma (DLBCL)
Esaam Sameir Ahmad;
Abstract
Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive non-Hodgkin lymphomas. It accounts for approximately 40% of lymphomas among adults.
Approximately 40-60% of patients with aggressive non-Hodgkin lymphoma (NHL) treated with standard anthracycl
Approximately 40-60% of patients with aggressive non-Hodgkin lymphoma (NHL) treated with standard anthracycl
Other data
| Title | Randomized Study of Rituximab-ICE versus Gemcitabine, Methylprednisolone, and Cisplatin in Patients with Recurrent / Refractory CD20+ Diffuse Large B-Cell Lymphoma (DLBCL) | Other Titles | دراسة فى استخدام عقار الريتوكسيماب مقارنة باستخدام الجيمسيتابين و الميثيل بريدنيزيلون و السيسبلاتين فى علاج الحالات المرتجعة أو المقاومة للعلاج للأورام الليمفاوية (ب) المنتشرة الكبيرة | Authors | Esaam Sameir Ahmad | Keywords | Randomized Study of Rituximab-ICE versus Gemcitabine, Methylprednisolone, and Cisplatin in Patients with Recurrent / Refractory CD20+ Diffuse Large B-Cell Lymphoma (DLBCL) | Issue Date | 2012 | Description | Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive non-Hodgkin lymphomas. It accounts for approximately 40% of lymphomas among adults. Approximately 40-60% of patients with aggressive non-Hodgkin lymphoma (NHL) treated with standard anthracycl |
Attached Files
| File | Size | Format | |
|---|---|---|---|
| 118643A5345.pdf | 205.34 kB | Adobe PDF | View/Open |
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.